A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors
Sponsor: BeiGene
Terminated
The research was terminated voluntarily due to changes in the company's business strategy regarding the development of BGB-24714, rather than any safety issues.
Other terminated trials from BeiGene
Other Solid Tumor, Adult trials with similar outcome
Listed as NCT05381909, this PHASE1 trial focuses on Solid Tumor, Adult and remains terminated or withdrawn. Sponsored by BeiGene, it has been updated 26 times since 2022, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
26 versions recorded-
Feb 2026 — Present [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
-
Oct 2025 — Feb 2026 [monthly]
Active Not Recruiting PHASE1
-
Sep 2025 — Oct 2025 [monthly]
Active Not Recruiting PHASE1
-
Aug 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE1
-
Jul 2025 — Aug 2025 [monthly]
Active Not Recruiting PHASE1
▶ Show 21 earlier versions
-
Jun 2025 — Jul 2025 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
May 2025 — Jun 2025 [monthly]
Recruiting PHASE1
-
Apr 2025 — May 2025 [monthly]
Recruiting PHASE1
-
Feb 2025 — Apr 2025 [monthly]
Recruiting PHASE1
-
Nov 2024 — Feb 2025 [monthly]
Recruiting PHASE1
-
Oct 2024 — Nov 2024 [monthly]
Recruiting PHASE1
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE1
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE1
-
May 2024 — Jun 2024 [monthly]
Recruiting PHASE1
-
Apr 2024 — May 2024 [monthly]
Recruiting PHASE1
-
Mar 2024 — Apr 2024 [monthly]
Recruiting PHASE1
-
Feb 2024 — Mar 2024 [monthly]
Recruiting PHASE1
-
Dec 2023 — Feb 2024 [monthly]
Recruiting PHASE1
-
Nov 2023 — Dec 2023 [monthly]
Recruiting PHASE1
-
Sep 2023 — Nov 2023 [monthly]
Recruiting PHASE1
-
Aug 2023 — Sep 2023 [monthly]
Recruiting PHASE1
-
Mar 2023 — Aug 2023 [monthly]
Recruiting PHASE1
-
Sep 2022 — Mar 2023 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jun 2022 — Sep 2022 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- BeiGene
For direct contact, visit the study record on ClinicalTrials.gov .